Human anaplastic lymphoma kinase (ALK) has been identified as an oncogene that is mutated or amplified in NBLs. To obtain a better understanding of the molecular events associated with ALK in the pathogenesis of NBL, it is necessary to clarify how ALK gene contributes to NBL progression. In the present study, we found that ALK expression was significantly high in NBL clinical samples with amplified MYCN (n 5 126, P , 0.01) and in developing tumors of MYCN-transgenic mice. Indeed, promoter analysis revealed that ALK is a direct transcriptional target of MYCN. Overexpression and knockdown of ALK demonstrated its function in cell proliferation, migration and invasion. Moreover, treatment with an ALK inhibitor, TAE-684, efficiently suppressed such biological effects in MYCN amplified cells and tumor growth of the xenograft in mice. Our present findings explore the fundamental understanding of ALK in order to develop novel therapeutic tools by targeting ALK for aggressive NBL treatment. N euroblastoma (NBL) is an embryonal malignancy derived from precursor cells of the sympathetic nervous system, and accounts for 7-10% of childhood cancers and around 15% of cancer deaths in children 1 . Though some subsets of NBL undergo spontaneous regression without therapy, about 60-70% of high-risk NBL patients are resistant to currently available therapies and have poor prognoses 1-3 . The genetic feature most consistently associated with treatment failure is an amplification of the MYCN proto-oncogene, which is strongly correlated with advanced disease 4-7 . Even in otherwise favorable localized disease, MYCN amplification indicates poor outcome, underscoring its biological importance. Indeed, upregulation of MYCN in NBL cells resulted in accelerated proliferation, migration and invasion [8] [9] [10] [11] . Consistent with these observations, transgenic mice overexpressing MYCN in neural crest-derived tissues displayed frequent development of NBL 12 , suggesting that upregulated expression of MYCN is causative in the genesis and development of NBL in vivo. However, the role of MYCN expression and its molecular mechanisms to induce an aggressive phenotype are still unclear. Identification of its direct transcriptional target gene(s) may provide a novel insight into understanding the functional contribution of MYCN in malignant phenotypes of aggressive NBL.
Human anaplastic lymphoma kinase (ALK) has been identified as an oncogene that is mutated or amplified in NBLs. To obtain a better understanding of the molecular events associated with ALK in the pathogenesis of NBL, it is necessary to clarify how ALK gene contributes to NBL progression. In the present study, we found that ALK expression was significantly high in NBL clinical samples with amplified MYCN (n 5 126, P , 0.01) and in developing tumors of MYCN-transgenic mice. Indeed, promoter analysis revealed that ALK is a direct transcriptional target of MYCN. Overexpression and knockdown of ALK demonstrated its function in cell proliferation, migration and invasion. Moreover, treatment with an ALK inhibitor, TAE-684, efficiently suppressed such biological effects in MYCN amplified cells and tumor growth of the xenograft in mice. Our present findings explore the fundamental understanding of ALK in order to develop novel therapeutic tools by targeting ALK for aggressive NBL treatment. N euroblastoma (NBL) is an embryonal malignancy derived from precursor cells of the sympathetic nervous system, and accounts for 7-10% of childhood cancers and around 15% of cancer deaths in children 1 . Though some subsets of NBL undergo spontaneous regression without therapy, about 60-70% of high-risk NBL patients are resistant to currently available therapies and have poor prognoses [1] [2] [3] . The genetic feature most consistently associated with treatment failure is an amplification of the MYCN proto-oncogene, which is strongly correlated with advanced disease [4] [5] [6] [7] . Even in otherwise favorable localized disease, MYCN amplification indicates poor outcome, underscoring its biological importance. Indeed, upregulation of MYCN in NBL cells resulted in accelerated proliferation, migration and invasion [8] [9] [10] [11] . Consistent with these observations, transgenic mice overexpressing MYCN in neural crest-derived tissues displayed frequent development of NBL 12 , suggesting that upregulated expression of MYCN is causative in the genesis and development of NBL in vivo. However, the role of MYCN expression and its molecular mechanisms to induce an aggressive phenotype are still unclear. Identification of its direct transcriptional target gene(s) may provide a novel insight into understanding the functional contribution of MYCN in malignant phenotypes of aggressive NBL.
The MYC family of proto-oncogenes belongs to the basic helix-loop-helix leucine-zipper class of transcription factors. MYC proteins (MYCN and c-Myc) share several regions of homology and similar cellular functions that target proliferative pathways vital for cancer progression. Members of this family function as heterodimers with MAX, and exert transcriptional activity by specifically binding to a consensus E-box motif (CACGTG) located within the promoter regions of a diverse set of target genes [13] [14] [15] . Although a handful of MYCN target genes involved in MYCN-driven cell proliferation and apoptosis have been identified, the target genes responsible for MYCN-mediated cell migration and invasion remain elusive.
Anaplastic lymphoma kinase (ALK) has been identified as a gene upregulated in unfavorable NBL, suggesting a possible oncogenic role for this receptor tyrosine kinase, which was previously linked with NBL 16, 17 . Recently, ALK point mutations were described in 3-11% of sporadic NBL, and were found to be one of the most important types of mutations in hereditary NBL [18] [19] [20] [21] [22] . More recently, Passoni et al. described NBL patients with high levels of ALK expression without ALK gene mutations. They showed that regardless of mutation status, high ALK levels were strongly correlated with poor prognosis 23 . This correlation between high ALK levels and unfavorable prognosis was also confirmed by some other investigators [24] [25] [26] . Moreover, Di Paolo et al. demonstrated that RNA interference (RNAi)-based knockdown of ALK, regardless of its genetic status, showed reduced proliferation and increased apoptosis in NBL cells and inhibited NBL tumor growth as well as prolonged survival in vivo 27 .
In the present study, we found that ALK directly mediates MYCNinduced oncogenic properties. The promoter region of ALK gene contains a non-canonical E-box located upstream of the transcription initiation site, and MYC proteins bind onto the promoter region and regulate its transcription. Wild-type ALK functions as a modulator of proliferation as well as cell migration and invasion. In addition, those biological activities and tumor growth in xenograft model derived from NBL cell lines with MYCN amplification were inhibited by targeting wild-type ALK with TAE-684, suggesting that highly expressed ALK in MYCN amplified cells could be inhibited by ALK inhibitor in the same manner as mutated or amplified ALK. These findings may be beneficial to the understanding of the molecular mechanism of wild-type ALK function, and contribute to the development of a possible therapeutic strategy for ALK-expressing NBLs.
Results
ALK mRNA expression is associated with MYCN amplification and expression in neuroblastomas. The expression of MYCN and ALK mRNA was measured by quantitative real-time PCR (qRT-PCR) for cDNA samples obtained from NBL clinical tissues. MYCN expression was significantly higher in tumors with MYCN amplification than MYCN-non-amplified tumors (P , 0.001; Figure 1a ). In this subset of NBLs with MYCN amplification, mRNA expression of ALK was significantly higher as compared with MYCN-non-amplified tumors (P , 0.01; Figure 1a ). High expression of ALK was also observed in NBLs at stages 3, 4 and 4S (Figure 1b ), suggesting that ALK might contribute to an aggressiveness and metastasis of NBL.
Both MYCN and c-Myc regulates ALK expression. In a MYCN transgenic mice model, the expression of the human MYCN oncogene was targeted to neural crest cells with the use of a tyrosine hydroxylase promoter 12 . This promoter is active in migrating cells of the neural crest early in the development of sympathetic ganglia and the adrenal medulla from which NBLs often arise 28 . Expression of both human MYCN and endogenous Alk mRNA was induced in superior mesenteric ganglion (SMG) tissues of 2-week-old MYCNhemizygous mice (Figure 1c ), which continued in adrenal tumor tissues until the mice were at least 11 weeks old. Consistent with the transgenic mice data, overexpression of MYCN or c-Myc in NBL (wild-type ALK cell line; NBL-S and NLF, and mutated ALK cell line; SH-SY5Y) and non-NBL (U2OS and HeLa) cells induced ALK expression in dose-and time-dependent manners at the mRNA (Figures 2a-c and Supplementary Figure S1A ) and protein (Supplementary Figures S1B and C) levels. Next, we performed siRNAmediated knockdown of MYCN experiment in SK-N-AS cells as described previously 29 , and found that MYCN knockdown decreased expression of ALK (Figure 2d ). To confirm a possible relationship between MYCN and ALK, we employed MYCNinducible neuroblastoma cells (Tet21/N) derived from a parental neuroblastoma cell line, SHEP 8 . The Tet21/N cells constitutively expressed MYCN in the absence of tetracycline (Tc), whereas the addition of Tc to the culture decreased MYCN expression levels. At the indicated time points after Tc depletion, total RNA was prepared and subjected to RT-PCR. As shown in Figure 2e , Tc deprivation led to an induction of MYCN in association with a significant increase in the expression levels of ALK. In contrast, addition of Tc significantly reduced the expression levels of MYCN with a concomitant decrease in ALK expression levels (Figure 2e ), suggesting that ALK might be a direct transcriptional target of MYCN.
ALK is a direct transcriptional target of MYCN and c-Myc. To identify a possible promoter region of ALK gene, we generated luciferase reporter constructs containing 22056 bp to 130 bp fragments of ALK gene. We performed promoter study using NBL (mutated ALK cell line; SH-SY5Y and wild-type ALK cell line; SK-N-AS) and non-NBL (U2OS and HeLa) cells, which showed corelated regulation of ALK gene with MYCN or c-MYC expression ( Figures 2b-d and Supplementary Figure S1A ). An increase in luciferase activity was observed in cells transfected with pGL4.17 ALK (22056 bp) compared with empty pGL4.17-basic vector (Figure 3a and Supplementary Figure S2A ). The luciferase activity with pGL4.17 ALK (22056 bp) was enhanced by co-expression of increasing amounts of MYCN or c-Myc expression vector (Figure 3b and Supplementary Figure S2B ).
Next, we performed ChIP assays with anti-MYCN and anti-c-Myc antibodies to determine whether they could directly bind to the ALK promoter. As shown in Figure 3c , MYCN was recruited onto the ALK promoter region. Endogenous MYCN was recruited onto the same region in TNB1 cells (MYCN amplification and high expression of ALK, Supplementary Figure S7A ) but not in RISA cells (MYCN-nonamplified and low ALK expression). Moreover, in non-NBL cell lines, the recruitment of endogenous c-Myc was more obvious in A875 cells (high ALK expression, Supplementary Figure S7B ) than HeLa cells (low ALK expression) ( Figure 3c ). Since the region to which MYC proteins were recruited contains two possible E-boxes (E-box1 and E-box2), E-box deletions were introduced in the luciferase reporter construct (2350 bp). Deletion of the E-box1 and/or E-box2 resulted in a significant reduction of ALK gene promoter activity in SK-N-AS ( Figure 3d ) and HeLa cells (Supplementary Figure  S2C ).
ALK shows oncogenic potential in NBL cells. Consistent with previous reports 23, 30 , our results also showed that ectopic expression of wild-type or mutated (F1174L) ALK induced the phosphorylation of both ALK and an ALK-associated signaling molecule, AKT (Supplementary Figure S4A ). The siRNA-mediated knockdown of endogenous ALK resulted in reduced phosphorylation of AKT in NBL cells harboring a wild-type allele (Supplementary Figure S4B ). Next, we investigated cell growth study using NBL cells (SK-N-DZ, SK-N-AS and NBL-S), which showed activation of the downstream signaling molecule AKT by ALK overexpression (Supplementary Figure S4A ). We also performed siRNA mediated knockdown of ALK experiment in MYCN amplified NLF cells. Figure 4a and 4b shows that overexpression of ALK enhanced cell proliferation, whereas siRNA-mediated knockdown of ALK was correlated with an inhibition of proliferation of NBL cells. Colony formation assays also revealed that the number and size of ALK-expressing viable clones were higher than those of vector control cells (Figures 4c and 4d ).
To examine whether ALK contributes to metastatic activity of NBL cells, we performed wound healing assays in MYCN-non-amplified NBL (mutated ALK cell line; SH-SY5Y and wild-type ALK cell line; SK-N-AS) and low ALK expressing non-NBL (HeLa) cells, and found that ALK expression enhanced cell migration (Supplementary Figure S5 ). Consistent with these results, Boyden chamber migration and invasion assays also showed a significant increase in the number of migrated and invaded cells arising from ALK-expressing cells compared with the vector control cells (Figure 5a and Supplementary Figure S6A ). This study we performed using MYCN-non-amplified cell line SK-N-AS, as shown downstream signaling molecule AKT was activated upon ALK overexpression (Supplementary Figure S4A) , and low ALK expressing non-NBL cell line HeLa. Migration and invasion of NBL cells were significantly suppressed by knockdown of ALK expression ( Figure 5b and Supplementary Figure  S6B ). For knockdown of ALK experiment, we used MYCN-nonamplified NBL-S cells, which have a high expression of MYCN protein and invasive potency as described previously 10 , and phosphorylation of the downstream molecule AKT was reduced with ALK knockdown (Supplementary Figure S4B ). We also performed knockdown of ALK study in MYCN amplified cell line SK-N-DZ. Both cell lines have a wild-type ALK allele.
ALK mediates MYCN-induced oncogenesis. We next tested the effect of growth inhibitory stimulus such as retinoic acid (RA) on the proliferative and colony-forming ability of cells expressing wildtype or F1174L-mutant ALK. RA is a well known MYCN suppressor, and the addition of RA to proliferating NBL cells halts their division and leads to either differentiation or apoptosis [31] [32] [33] . We analyzed RA treatment experiment using MYCN amplified NBL cells (GOTO), which have a wild-type ALK allele and showed sensitivity to RA as previously described 33 . Figures 6a and b showed that after treatment with RA, the proliferation as well as the number and size of colony of NBL cells were significantly suppressed. As expected, MYCN expression was decreased after RA treatment, and ALK expression was also downregulated ( Figure 6c ). However, both wild-type and F1174L mutated ALK-overexpressing cells had a higher number of live clones compared with the control cells following treatment with RA, suggesting that the prior ALK expression partially prevented the effect of RA on cell proliferation.
We also examined the effect of MYCN-induced cell migration in the presence or absence of ALK expression. This study we performed using NBL-S cells, which showed upregulation of endogenous ALK with MYCN overexpression (Figure 2a and Supplementary Figure  S1B ). Consistent with previous reports 10, 11 , MYCN expression enhanced cell migration. As expected, the migration was suppressed by siRNA-mediated knockdown of ALK in NBL cells (Figure 6d ), suggesting that MYCN function in cell migration is at least partly regulated by ALK expression. Figure S8 ). In addition, TAE-684 treatment significantly suppressed tumor growth of xenograft generated from MYCN amplified NBL cells (SK-N-DZ and NLF) ( Figure 7c ).
Discussion
MYCN amplification occurs in approximately 25% of primary NBLs and is one of the most reliable prognostic factors identified to date 1,5-7 . It is significantly associated with advanced disease stages, rapid tumor progression and poor prognosis. However, the molecular mechanisms how MYCN induces aggressive NBL have not yet been fully elucidated. Our present findings clearly provided the evidence that MYCN-mediated ALK induction promotes cell proliferation, migration and invasion.
To our knowledge, this is the first report showing a direct role of MYCN in the transcriptional regulation of ALK in NBL. Consistent with the evidence that ALK expression was significantly correlated with MYCN amplification in primary NBLs, overexpression of MYCN induced promoter activity of the ALK gene, leading to a high level of ALK expression in NBL cells. The induction of ALK expression was also observed in non-NBL cells, suggesting that the transcription of ALK gene is generally regulated by MYCN. Moreover, in agreement with the previous results showing that c-Myc recognizes and binds to the E-box in the same manner as MYCN 14, 15, 34 , ALK expression was also transcriptionally regulated by c-Myc in non-NBL cells. Taking this into account, ALK is a direct target gene of MYC proteins. Our data are also informative to explain why ALK expression is high in MYCN transgenic mice. High levels of ALK expression were observed in 2-week-old MYCN-hemizygous mice, indicating that a spontaneously arising NBL expresses ALK in the early stage of tumor development driven by MYCN. Recently, PHOX2b has been reported as a transcription factor targeting ALK 35 . While the researchers identified transcriptional activity in the promoter construct of ALK gene from 2672 to 1384 bp, we observed comparable basal promoter activity in the 2350 to 130 bp promoter region that More recently, Schonheer et al. showed that both wild-type and gain-of-function ALK mutants were able to stimulate transcription at the MYCN promoter through the activation of a downstream molecule, ERK, and initiate mRNA transcription of MYCN in both neuronal and NBL cells 36 . Furthermore, Berry et al. demonstrated that the F1174L mutation of ALK enhanced MYCN protein stabilization and found that endogenous Mycn mRNA was upregulated in the tumors of MYCN/ALKF1174L transgenic mice 37 . Taken together, these data suggest a positive feedback loop for MYCN which, in turn, directly regulates ALK expression to potentiate the oncogenic activity of MYCN, leading to rapid malignant transformation.
The theory that ALK overexpression contributes to oncogenic activity is supported by the data obtained from patients with NBL. As described previously, high expression of ALK mRNA 25, 26 and/or protein 23, 24 was significantly correlated with poor outcome of NBL. Consistent with these earlier reports, our present data clearly showed that aggressive and metastatic NBLs (stages 3, 4 and 4s) exhibited a significantly higher expression level of ALK mRNA compared with localized and favorable NBLs (stages 1 and 2), suggesting an onco- genic relevance of ALK in NBL. Previously obtained evidence has indicated an important role of ALK in both familial and sporadic NBL pathogenesis [18] [19] [20] [21] [22] . However, the contribution of wild-type ALK to NBL development was not well understood. Intensive studies have been mainly performed examining a correlation between activating mutations in the tyrosine kinase (TK) domain of ALK and poor clinical outcome in NBLs. However, mutations in the TK domain are observed in limited cases. According to De Brouwer and colleagues, only 6.9% missense mutations and 1.7% focal amplifications in ALK gene were detected among 709 NBL patients 25 . They have also revealed that there were no significant survival differences observed in tumors with or without ALK mutations or amplifications 25 , suggesting that wild-type ALK might have an important role in NBL pathogenesis. Consistent with Passoni et al. and Di Paolo et al., our present findings indicate that wild-type ALK can exert oncogenic activity in NBL cells, in addition to its mutated isoforms.
In the current study, overexpression of either wild-type or mutated ALK partially restored the decreased cell proliferation caused by RA treatment, implicating that RA-mediated reduction of MYCN expression resulted in decreased cell proliferation partially through the downregulation of ALK expression. The contribution of native ALK to migration and invasion implies a role for ALK in tumor progression and metastasis of NBLs. MYCN-induced cell migration was also inhibited by siRNA-mediated knockdown of ALK, suggesting that ALK is one of the key target genes of MYCN to conduct NBL cell migration. Moreover, treatment with TAE-684 effectively inhibited cell proliferation, migration and invasion of NBL cells with MYCN amplification compared to MYCN-non-amplified cells. Xenograft tumors derived from MYCN amplified NBL cells were significantly suppressed with TAE-684 treatment, indicating that ALK had a pivotal role in the development of NBL with MYCN amplification. Taken together, these data provide an important and direct mechanism by which MYCN is able to sensitize cells and tumors to aggressive characteristics through the regulation of ALK expression.
In conclusion, this study provides several lines of evidence that ALK is a direct transcriptional target of MYC proteins and a key molecule for MYC proteins to exert influence towards oncogenesis. Thus, our present findings might help to explain a novel molecular mechanism for the development and progression of aggressive NBL with or without MYCN amplification, and suggest that a therapy targeting ALK should be considered in combination with more conventional agents to treat NBLs with high expression of ALK.
Methods
Patient population. One hundred and twenty-six patients with NBL were diagnosed clinically and histologically, using surgically removed tumor specimens according to the International Neuroblastoma Pathological Classification (INPC). According to the International NBL Staging System (INSS) 38 , 22 patients were diagnosed as stage 1, 12 were stage 2, 23 were stage 3, 63 were stage 4, and 6 were stage 4S. MYCN and ALK amplification were determined using fluorescence in situ hybridization (FISH). This study was approved by the Ethics Committee of the Faculty of Biology and Medicine at the Chiba Cancer Center, and appropriate informed consent was obtained from all patients.
Transgenic mice samples collection and RT-PCR. Tyrosine hydroxylase (TH)-MYCN mice were maintained through hemizygotic matings, as previously described 39 . Superior mesenteric ganglion (SMG) tissues were obtained from 2-weekold wild-type or MYCN-hemizygous mice (n 5 3 mice per group). Adrenal gland tumor tissues were collected from 9-, 10-or 11-week-old MYCN-hemizygous mice (n 5 3 mice per group). All animals were handled in accordance with institutional guidelines for safe and ethical treatment of mice, and this study was approved by the Animal Care and Use Committee of Nagoya University Graduate School of Medicine. Total RNA extraction was performed using ISOGEN (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. cDNA was generated from total RNA using SuperScript III reverse transcriptase and random primers following the manufacturer's recommendations (Invitrogen, Carlsbad, CA, USA). The resultant cDNAs were subjected to PCR-based amplification using the following primer Plasmid constructs. ALK promoter construct and different deletion constructs of ALK promoter were generated using an In-Fusion HD Cloning Kit (Clontech Laboratories, Mountain View, CA, USA) and inserted into the luciferase pGL4.17basic plasmid (Promega, Madison, WI, USA). The protein coding region of c-Myc was inserted into the pcDNA3 plasmid (Invitrogen). pcDNA3-ALK wild-type and pcDNA3-ALK (F1174L ALK mutation) mutated expression plasmids were kindly provided by Dr. J. Takita (The University of Tokyo, Tokyo, Japan). pUHD-MYCN expression plasmid was kindly provided by Dr. M. Schwab (German Cancer Research Center, Heidelberg, Germany). All constructs were verified by DNA sequencing.
RNA isolation and RT-PCR. Total RNA was prepared from the indicated cell lines using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's recommendations. cDNA was generated from total RNA using SuperScript II reverse transcriptase and random primers following the manufacturer's conditions (Invitrogen). The resultant cDNAs were subjected to PCR-based amplification using the following primer sets and annealing temperatures To control for the integrity and uniformity of the sample preparation, GAPDH mRNA was amplified. All PCR amplifications were carried out with a GeneAmp PCR 9700 (Applied Biosystems, Foster City, CA, USA), using rTaq DNA polymerase (Takara, Shiga, Japan). PCR products were separated by 2.0% agarose gel electrophoresis and stained with ethidium bromide.
Quantitative real-time PCR (qRT-PCR). Total RNA was extracted from clinical samples and NBL as well as non-NBL cell lines using TRIzol reagent (Invitrogen) according to the manufacturer's instructions, and reverse transcription was performed with SuperScript II reverse transcriptase (Invitrogen). qRT-PCR was carried out using an ABI Prism 7700 sequence detection system (Applied Biosystems), according to the manufacturer's protocol. TaqMan probe for ALK www.nature.com/scientificreports 59-GUUGGGGUCAUAGAUGUUU-39, 59-UGAUUAUUUUACAUGGAAU-39, 59-GGAGGUGGCUGGAAUGAUA-39 (Thermo Fisher Scientific) according to the manufacturer's recommendations. Seventy-two hours after transfection, cell lysates were prepared and analyzed for ALK and GAPDH expression levels by qRT-PCR or the expression levels of ALK, pALK, AKT and pAKT by immunoblotting analysis.
Site-specific deletion. The luciferase reporter constructs (2350 bp)-D E1 and (2350 bp)-DE 1/2 deletion constructs were generated with QuikChange Site-Directed Mutagenesis System (Invitrogen) on the basis of the parental construct (2350 bp), according to the manufacturer's instructions. The following primer sets were used: (2350 bp)-DE1, 59-GCGCGGCTCAGCCAGCTGGCGGGCGCCCAG-39 (sense) and 59-CATCTGCCTGGGCGCCCGCCAGCTGGCTGAG-39 (antisense); (2350 bp)-DE2, 59-GCAGCAGCGCGGAGTTGGAGCCCCGCCCC-39 (sense) and 59-CCCGGAGGGGGCGGGGCTCCAACTCCGCG-39 (antisense). The deletions were verified by DNA sequencing.
Luciferase reporter assays. Cells (5 3 10 4 ) were seeded in 12-well cell culture plates (Becton Dickinson, NJ, USA) and allowed to adhere overnight. Cells were then cotransfected with expression plasmid, luciferase reporter construct and pRL-TK Renilla luciferase cDNA. Total amounts of plasmid DNA per transfection were kept constant with empty plasmid pcDNA3 and/or pGL4.17. Forty-eight hours after transfection, cells were lysed, and both firefly and Renilla luciferase activities were measured with the Dual-Luciferase Reporter Assay system (Promega), according to the manufacturer's instructions. The firefly luminescence signal was normalized based on the Renilla luminescence signal.
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed using a chromatin immunoprecipitation assay kit according to the protocol provided by Millipore (Bedford, MA, USA). In brief, TNB1 (high ALK expression), RISA (low ALK expression), A-875 (high ALK expression) and HeLa cells (low ALK expression) were cross-linked with formaldehyde, and cross-linked chromatin was sonicated followed by immunoprecipitation with anti-IgG (Cell Signaling), polyclonal anti-MYCN and/or monoclonal anti-c-Myc (anti-MYC-Tag (9B11)) antibody. DNA of the immunoprecipitates and control input DNA were purified and then analyzed by standard PCR using the following primer sets: F1 (2350), 59-GCTCGCTAGCCTC GAAGTTCTCACATTTGCTCC-39 (sense); R1 (130), 59-TCTTGATATCCTCG AGTACCAGCTGCTACC-39 (antisense) and F2(-1813), 59-GGAGAGGGGTATTA TTAGAGAACG-39 (sense); R2 (21433), 59-GGGCAAAGAATTATCTCACCC-39 (antisense).
Cell proliferation assays. Cells (1 3 10 3 ) were seeded in 96-well cell culture plates (Becton Dickinson, NJ, USA) and allowed to adhere overnight. At the indicated time points, cell proliferation was measured using a cell counting kit-8 (Dojindo, Kumamoto, Japan) according to manufacturer's instructions.
Colony formation assays. Cells were seeded at a final density of 2 3 10 4 cells per well in 6-well cell culture plates (Becton Dickinson, NJ, USA) and allowed to attach overnight. Cells were then transfected with the empty or pcDNA3-ALK expression plasmid. Forty-eight hours after transfection, cells were transferred to the fresh medium containing G418. After 14 days, viable colonies were washed in PBS, fixed with 4% paraformaldehyde (PFA) and stained with crystal violet solution.
Retinoic acid treatment. To study the effect of retinoic acid (RA, Sigma, St. Louis, MO, USA) on the proliferation or colony formation of GOTO cells expressing wildtype or mutated ALK, transfected cells were grown in normal growth medium, and dimethylsulfoxide (DMSO) or 10 mM RA (with 50 mg/ml of G418 for colony formation assays) was added to the medium the following day. The culture medium was changed every 48 h to replenish the RA and G418. Cell viability and colony formation assays were performed as described above.
Cell migration and invasion assays. Cell motility was measured using 8-mm pore size FluoroBlok Transwell chambers (BD Biosciences, San Diego, CA, USA). Cells were collected by a brief treatment with trypsin/EDTA solution, washed once with serumcontaining medium, centrifuged, resuspended in medium containing 0.1% bovine serum albumin, and then placed in the inserts at a concentration of 2.5 3 10 4 cells in 250 ml (migration assays) or 5 3 10 4 cells in 250 ml (invasion assays). In the lower compartments of the chambers, 750 ml of medium containing 10% FBS was added as a chemoattractant. Invasion assays were carried out by the same procedure except that the filters of the Transwell chambers were coated with 50 mg Matrigel (BD Biosciences). After incubation at 37uC for 16 h (migration assays) or 24 h (invasion assays), cells that migrated through the pores to the lower chamber were stained with Giemsa solution or 1 mM Calcein AM (Invitrogen). Stained cells were analyzed by either counting under the microscope or by detecting the fluorescence intensity using microplate reader (Perkin-Elmer, Waltham, MA, USA).
Immunoblot analysis.
Immunoblotting was performed as previously described 40 using the following antibodies: monoclonal anti-ALK was from Beckman Coulter (Marseille, France), polyclonal anti-phosphorylated Tyr-1604 ALK, polyclonal anti-AKT, polyclonal anti-phosphorylated AKT Ser-473, polyclonal anti-MYCN and monoclonal anti-MYC-Tag (9B11) were from Cell Signaling (Danvers, MA, USA), polyclonal anti-Actin was from Sigma-Aldrich (St. Louis, MO, USA). All antibodies were used at a dilution of 151000 in immunoblot analysis.
Drug treatment. ALK inhibitors, TAE-684 41, 42 and CH5424802 43 were purchased from Active Biochemicals (Hong Kong, China), and crizotinib 36, 37, 44 was purchased from Selleck (Houston, TX, USA). For cell proliferation assay; NBL cells (3 3 10 3 ) were seeded in 96-well cell culture plates and treated with varying concentrations of TAE-684, crizotinib or CH5424802 for 72 h and cell proliferation was measured as described above. The IC 50 (half maximal inhibitory concentration) values of NBL cells were calculated by nonlinear regression (variable slope) using the GraphPad Prism 6 software (La Jolla, CA, USA). Cell migration and invasion assay; cell migration and invasion assays were performed as described above with or without the treatment of 50 nM or 200 nM of TAE-684, crizotinib or CH5424802.
Xenograft study; NBL cells with MYCN amplification (SK-N-DZ and NLF) were subcutaneously injected (5 3 10 6 cells/inoculate in RPMI 1640 together with an equal volume of Matrigel, Becton Dickinson) in the right flank of C.B-17-SCID female mice at 6 weeks old. After implantation, tumor sizes were measured using the following formula: [(width) 2 3 length]/2. Treatment of TAE-684 was initiated at the time when tumor size exceeds 85 mm 3 . TAE-684 was resuspended in 10% N-methyl-2-pyrrolidinone (Wako, Osaka, Japan)-90% PEG (polyethylene glycol, molecular weight 300) (Wako) solution. Mice were administered TAE-684 (10 mg/kg) by oral gavage once daily. All mice were housed in a pathogen-free conditions strictly following the Chiba Cancer Center Research Institute guidelines, and these studies were approved by the Institutional Animal Care and Use Committee of Chiba Cancer Center Research Institute.
Data analysis. Results were expressed as the mean 6 SD. Student's t tests and twoindependent samples t tests were used to compare the differences in the means of different groups. P values of ,0.05 were considered statistically significant. P values of ,0.05, ,0.01 and ,0.001 were denoted by a single asterisk, double asterisks and triple asterisks, respectively. n.s. indicates not significant at the 0.05 probability level.
